British-Swedish drugmaker AstraZeneca is set to launch 15 new products in India from 2023 to 2025, focusing on oncology, cardiovascular, renal, and metabolic diseases, respiratory and immunology, and rare diseases. The company aims to expand access to its therapies through public-private partnerships, licensing deals, and tiered pricing. AstraZeneca's India business returned to growth in FY23 after a period of plateauing sales, driven by innovative molecules.